POD24 AND CR30 ARE PROMISING SURROGATE ENDPOINTS FOR ASSESSING THE OUTCOME OF PATIENTS WITH ADVANCED STAGE FOLLICULAR LYMPHOMA ENROLLED IN THE FOLL05 TRIAL BY FIL.

MLA

Luminari, S., et al. “Pod24 and Cr30 Are Promising Surrogate Endpoints for Assessing the Outcome of Patients with Advanced Stage Follicular Lymphoma Enrolled in the Foll05 Trial by Fil.” Hematological Oncology, vol. 35, June 2017, pp. 228–29. EBSCOhost, https://doi.org/10.1002/hon.2438_91.

APA

Luminari, S., Marcheselli, L., Manni, M., Anastasia, A., Vitolo, U., Chiarenza, A., Rigacci, L., Angelucci, E., Fama, A., Pulsoni, A., Rattotti, S., Angrilli, F., Gaidano, G., Stelitano, C., Bertoldero, G., Cascavilla, N., Salvi, F., Ferreri, A. J., Tarantino, V., & Bellei, M. (2017). Pod24 and Cr30 Are Promising Surrogate Endpoints for Assessing the Outcome of Patients with Advanced Stage Follicular Lymphoma Enrolled in the Foll05 Trial by Fil. Hematological Oncology, 35, 228–229. https://doi.org/10.1002/hon.2438_91

Chicago

Luminari, S., L. Marcheselli, M. Manni, A. Anastasia, U. Vitolo, A. Chiarenza, L. Rigacci, et al. 2017. “Pod24 and Cr30 Are Promising Surrogate Endpoints for Assessing the Outcome of Patients with Advanced Stage Follicular Lymphoma Enrolled in the Foll05 Trial by Fil.” Hematological Oncology 35 (June): 228–29. doi:10.1002/hon.2438_91.